Compare ADMA Biologics Inc (ADMA) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while State Street SPDR S&P Homebuilders ETF trades at $106.06. The key difference: State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | XHB | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $121.36 |
52-Week Low | $7.60 | $94.86 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
XHB (SPDR S&P Homebuilders ETF) trades at $111.29, down 1.13% amid mixed housing data. Technical indicators show a bullish bias with strong moving average support, while oscillators remain neutral. Recent news highlights declining new home sales but improving builder sentiment, creating a complex backdrop for the homebuilding sector.
The ETF faces headwinds from higher mortgage rates and construction costs, but potential exists if housing demand recovers. Key risks include interest rate sensitivity and economic uncertainty, while technical support near $108 provides a cushion for near-term stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
